Synthesis and β-amyloid binding properties of rhenium 2-phenylbenzothiazoles

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 8, 2009, Pages 2258-2262

  Lin, Kuo Shyan ^a   Debnath, Manik L ^a   Mathis, Chester A ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid plaques; Alzheimer's disease; PiB; Rhenium; SPECT; Technetium 99m

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; BENZOTHIAZOLE DERIVATIVE; PITTSBURGH COMPOUND B DERIVATIVE; RHENIUM; RHENIUM 2 PHENYLBENZOTHIAZOLE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; MOLECULAR IMAGING; REACTION ANALYSIS; STRUCTURE ANALYSIS;

AMYLOID BETA-PROTEIN; PROTEIN BINDING; RHENIUM; THIAZOLES;

EID: 63149151674     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.02.096     Document Type: Article

References (29)

1. Hardy J., and Selkoe D.J. Science 297 (2002) 353
2. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., and Rowe C.C. Brain 130 (2007) 2837
3. Pangalos M.N., Jacobsen S.J., and Reinhart P.H. Biochem. Soc. Trans. 33 (2005) 553
4. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., and Barrio J.R. Am. J. Geriatr. Psychiatry 10 (2002) 24
5. Klunk W.E., Engler H., Nordberg A., Wang Y.M., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., and Langstrom B. Ann. Neurol. 55 (2004) 306
6. Verhoeff N.P.L.G., Wilson A.A., Takeshita S., Trop L., Hussey D., Singh K., Kung H.F., Kung M.P., and Houle S. Am. J. Geriatr. Psychiatry 12 (2004) 584
7. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K., and Arai H. J. Nucl. Med. 48 (2007) 553
8. Mathis, C.A. Abstract of Papers, 54th Society of Nuclear Medicine Annual Meeting, Washington, DC. Society of Nuclear Medicine: Reston, VA, 2007; Abstract 187.
9. Rowe, C.C. Abstract of Papers, 54th Society of Nuclear Medicine Annual Meeting, Washington, DC. Society of Nuclear Medicine: Reston, VA, 2007; Abstract 188.
10. Friedland R.P., Majocha R.E., Reno J.M., Lyle L.R., and Marotta C.A. Mol. Neurobiol. 9 (1994) 107
11. Han H., Cho C.G., and Lansbury P.T. J. Am. Chem. Soc. (1996) 118: 4506
12. Zhen W., Han H., Anguiano M., Lemere C.A., Cho C.G., and Lansbury P.T. J. Med. Chem. 42 (1999) 2805
13. Dezutter N.A., Dom R.J., de Groot T.J., Bormans G.M., and Verbruggen A.M. Eur. J. Nucl. Med. 26 (1999) 1392
14. Zhuang Z.P., Kung M.P., Hou C., Ploessl K., and Kung H.F. Nucl. Med. Biol. 32 (2005) 171
15. Kung, H.F. Abstract of Papers, 16th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia. Society of Radiopharmaceutical Sciences: Reston, VA, 2005; Abstract 251.
16. Chen X., Yu P., Zhang L., and Liu B. Bioorg. Med. Chem. Lett. 18 (2008) 1442
17. Le Gal J., Latapie L., Gressier M., Coulais Y., Dartiguenave M., and Benoist E. Org. Biomol. Chem. 2 (2004) 876
18. Mathis C.A., Wang Y., and Klunk W.E. Curr. Pharm. Des. 10 (2004) 1469
19. Mathis C.A., Wang Y.M., Holt D.P., Huang G.F., Debnath M.L., and Klunk W.E. J. Med. Chem. 46 (2003) 2740
20. Klunk W.E., Wang Y.M., Huang G.F., Debnath M.L., Holt D.P., and Mathis C.A. Life Sci. 69 (2001) 1471
21. Mathis C.A., Bacskai B.J., Kajdasz S.T., McLellan M.E., Frosch M.P., Hyman B.T., Holt D.P., Wang Y.M., Huang G.F., Debnath M.L., and Klunk W.E. Bioorg. Med. Chem. Lett. 12 (2002) 295
22. Oya S., Plossl K., Kung M.P., Stevenson D.A., and Kung H.F. Nucl. Med. Biol. 25 (1998) 135
23. Hansen L., Cini R., Taylor Jr. A., and Marzilli L.G. Inorg. Chem. 31 (1992) 2801
24. Le Gal J., Tisato F., Bandoli G., Gressier M., Jaud J., Michaud S., Dartiguenave M., and Benoist E. Dalton Trans. 23 (2005) 3800
25. 3 (208 mg, 0.25 mmol) and NaOAc methanolic solution (1.0 M, 20 mL) were added to the residue, and the resulting solution was heated at 75 °C for 24 h. After cooling to rt, the solution was diluted with water (50 mL), and extracted with ethyl acetate (50 mL). The ethyl acetate phase was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The crude product was purified by chromatography on silica gel eluting with 10:90 methanol/ethyl acetate to give the expected product in 17-41% yields.
26. 6): 2.09-2.21 (m, 1H), 2.81-2.92 (m, 1H), 2.95-3.03 (m, 1H), 3.14-3.24 (m, 1H), 3.60-3.71 (m, 1H), 3.83 (s, 3H), 3.85-4.03 (m, 2H), 4.34-4.44 (m, 1H), 6.97 (d, J = 8.1 Hz, 1H), 7.07 (dd, J = 8.9, 2.3 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 2.3 Hz, 1H), 7.84 (d, J = 8.9 Hz, 1H), 9.45 (s, 1H).
27. 2 (M+H) 576.0426, found 576.0432.
28. Kagotani, H. Japan Patent 2000219674, 2000.
29. Chandra R., Oya S., Kung M.-P., Hou C., Jin L.-Y., and Kung H.F. J. Med. Chem. 50 (2007) 2415